Loading company…
Xianshengzaiming Pharmaceutical develops and commercializes anti-tumor drugs.
Founded in 2020 and based in Haikou, China, Xianshengzaiming Pharmaceutical is a subsidiary of Simcere Pharmaceutical Group. It focuses on drug development in lung cancer, gastrointestinal oncology and gynecological oncology, and offers R&D services including protein engineering, AI-assisted molecular design, protein degraders and ADCs. Its products include Trilaciclib Hydrochloride for Injection, Envafolimab and Recombinant Human Endostatin Injection. In June 2025, it received venture funding from Tppoly Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in